{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T05:23:50Z","timestamp":1767677030524},"reference-count":116,"publisher":"FapUNIFESP (SciELO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Sao Paulo Med. J."],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p>CONTEXT AND OBJECTIVE: According to some cohort studies, the prevalence of refractory schizophrenia (RS) is 20-40%. Our aim was to evaluate the effectiveness and safety of aripiprazole, paliperidone, quetiapine and risperidone for treating RS. METHODS: This was a critical appraisal of Cochrane reviews published in the Cochrane Library, supplemented with reference to more recent randomized controlled trials (RCTs) on RS. The following databases were searched: Medical Literature Analysis and Retrieval System Online (Medline) (1966-2009), Controlled Trials of the Cochrane Collaboration (2009, Issue 2), Embase (Excerpta Medica) (1980-2009), Literatura Latino-Americana e do Caribe em Ci\u00eancias da Sa\u00fade (Lilacs) (1982-2009). There was no language restriction. Randomized controlled trials, systematic reviews and meta-analyses evaluating atypical antipsychotics for treating RS were included. RESULTS: Seven Cochrane systematic reviews and 10 additional RCTs were included in this review. The data generally showed minor differences between the atypical antipsychotics evaluated and typical antipsychotics, regarding improvement in disease symptoms, despite better adherence to treatment with atypical antipsychotics. Risperidone was specifically evaluated in patients with RS in one of the systematic reviews included, with favorable outcomes, but without definitive superiority compared with other drugs of proven efficacy, like amisulpride, clozapine and olanzapine. CONCLUSIONS: The findings underscore the difficulty in treating these patients, with high dropout rates and treatment patterns of modest improvement in assessments of effectiveness. Atypical antipsychotics have advantages over typical antipsychotics mainly through their better safety profile, which leads to better adherence to treatment. A combination of antipsychotics may also be an option for some refractory patients.<\/jats:p>","DOI":"10.1590\/s1516-31802010000300007","type":"journal-article","created":{"date-parts":[[2010,10,16]],"date-time":"2010-10-16T21:56:35Z","timestamp":1287266195000},"page":"141-166","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews"],"prefix":"10.1590","volume":"128","author":[{"given":"Tamara","family":"Melnik","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardo Garcia","family":"Soares","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eduarda dos Santos","family":"Puga","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro Nagib","family":"Atallah","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma D","year":"1998","journal-title":"Schizophr Bull","ISSN":"http:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"key":"ref2","series-title":"Schizophrenia","first-page":"489","volume-title":"Treatment-resistant schizophrenia","author":"Barnes TRE","year":"2003","edition":"2"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/15622970510030027","article-title":"Some biological correlates of drug resistance in schizophrenia: a multidimensional approach","volume":"6","author":"Altamura AC","year":"2005","journal-title":"World J Biol Psychiatry"},{"issue":"4","key":"ref4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1176\/ajp.154.4.475","article-title":"Age at onset and gender of schizophrenic patients in relation to neuroleptic resistance","volume":"154","author":"Meltzer HY","year":"1997","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"1-3","key":"ref5","first-page":"281","article-title":"Predictors of response and outcome in treatment resistant versus non treatment resistant schizophrenic patients","volume":"36","author":"Henna J","year":"1999","journal-title":"Schizophrenia Research","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"key":"ref6","series-title":"Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia","year":"2002"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/schbul\/16.4.551","article-title":"Defining treatment refractoriness in schizophrenia","volume":"16","author":"Brenner HD","year":"1990","journal-title":"Schizophr Bull","ISSN":"http:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine","volume":"45","author":"Kane J","year":"1988","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"2","key":"ref9","first-page":"CD004578","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh HG","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ref10","first-page":"CD006617","article-title":"Aripiprazole versus typical antipsychotic drugs for schizophrenia","author":"Bhattacharjee J","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref11","first-page":"CD006369","article-title":"Paliperidone for schizophrenia","author":"Nussbaum AM","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref12","first-page":"CD000967","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont M","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref13","first-page":"CD000440","article-title":"Risperidone versus typical antipsychotic medication for schizophrenia","author":"Hunter RH","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"ref14","first-page":"CD002306","article-title":"Risperidone versus other atypical antipsychotic medication for schizophrenia","author":"Gilbody SM","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"ref15","first-page":"CD005237","article-title":"Risperidone versus olanzapine for schizophrenia","author":"Jayaram MB","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"ref16","first-page":"MR000023","article-title":"When and how to update systematic reviews","author":"Moher D","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","author":"Carson WH","year":"2002"},{"key":"ref18","author":"Kane J","year":"2003"},{"key":"ref19","author":"Daniel DG","year":"2004"},{"key":"ref20","author":"Oren D","year":"2005"},{"key":"ref21","author":"Carson WH","year":"2000"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"S309","DOI":"10.1016\/S0924-977X(00)80358-2","article-title":"Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo","volume":"10","author":"Carson WH","year":"2000","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"2","key":"ref23","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0193-953X(02)00113-2","article-title":"Treatment of schizophrenia: preventing the progression of disease","volume":"26","author":"Csernansky JG","year":"2003","journal-title":"Psychiatr Clin North Am","ISSN":"http:\/\/id.crossref.org\/issn\/0193-953X","issn-type":"print"},{"key":"ref24","article-title":"Aripiprazole, a novel antipsychotic: overview of a phase II study result","volume":"3","author":"Daniel DG","year":"2000","journal-title":"International Journal of Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/1461-1457","issn-type":"print"},{"key":"ref25","article-title":"Aripiprazole for long-term maintenance treatment of schizophrenia","volume":"5","author":"Kujawa M","year":"2002","journal-title":"International Journal of Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/1461-1457","issn-type":"print"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","article-title":"Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial","volume":"69","author":"Chang JS","year":"2008","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4088\/JCP.v68n0206","article-title":"Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine","volume":"68","author":"Kane JM","year":"2007","journal-title":"J Clin Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0160-6689","issn-type":"print"},{"issue":"1-3","key":"ref28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","article-title":"Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study","volume":"93","author":"Davidson M","year":"2007","journal-title":"Schizophr Res","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JCP.0b013e31802dda4a","article-title":"Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"27","author":"Kramer M","year":"2007","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.biopsych.2007.01.017","article-title":"Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study","volume":"62","author":"Marder SR","year":"2007","journal-title":"Biol Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref31","author":"Tzimos A","year":"2006"},{"issue":"5","key":"ref32","first-page":"949","article-title":"Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia","volume":"4","author":"Turkoz I","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1176\/appi.ajp.2009.08040613","article-title":"Randomized, double-blind, placebo-controlled study of paliperidone extended-release quetiapine in inpatients with recently exacerbated schizophrenia","volume":"166","author":"Canuso CM","year":"2009","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0924-977X(94)90211-9","article-title":"A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of SeroquelTM in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia","volume":"4","author":"Hirsch S","year":"1994","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref35","first-page":"346","article-title":"'Seroquel' treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens","volume":"5","author":"Link CGG","year":"1995","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1001\/archpsyc.1997.01830180067009","article-title":"Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Seroquel Study Group","volume":"54","author":"Small JG","year":"1997","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"key":"ref37","author":"Addington DE","year":"1996"},{"key":"ref38","doi-asserted-by":"crossref","DOI":"10.1016\/0924-977X(96)87987-9","article-title":"'Seroquel' (ICI 204,636): an atypical antipsychotic: results from a multiple fixed dose, placebo-controlled study","volume":"6","author":"Arvanitis LA","year":"1996","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref39","author":"Arvanitis LA","year":"1996"},{"key":"ref40","author":"Arvanitis LA","year":"1997"},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group","volume":"42","author":"Arvanitis LA","year":"1997","journal-title":"Biol Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref42","article-title":"ICI 204,636, an atypical antipsychotic: results from a multiple fixed-dose, placebo-controlled trial","volume":"32","author":"Arvanitis LA","year":"1966","journal-title":"Psychopharmacology Bulletin","ISSN":"http:\/\/id.crossref.org\/issn\/0048-5764","issn-type":"print"},{"issue":"2-3","key":"ref43","doi-asserted-by":"crossref","DOI":"10.1016\/0920-9964(96)85441-7","article-title":"A comparison of five fixed doses of 'seroquel' (ICI 204,636) with haloperidol and placebo in patients with schizophrenia","volume":"18","author":"Borison RL","year":"1996","journal-title":"Schizophrenia Research","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/0006-3223(96)84278-8","article-title":"A multiple fixed-dose, placebo-controlled trial with 'seroquel': An atypical antipsychotic","volume":"39","author":"Borison RL","year":"1996","journal-title":"Biological Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref45","author":"Cantillon M","year":"1998"},{"key":"ref46","author":"Cantillon M","year":"1998"},{"key":"ref47","author":"Cantillon M","year":"1998"},{"key":"ref48","article-title":"'Seroquel' (ICI 204,636): not different from placebo for EPS or prolactin","volume":"39","author":"Hong WW","year":"1996","journal-title":"Biological Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"key":"ref49","article-title":"'Seroquel' (ICI 204-636) does not differ from placebo in the incidence of EPS or effect on plasma prolactin","volume":"6","author":"Hong WW","year":"1996","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref50","author":"Hong WW","year":"1996"},{"key":"ref51","author":"Hong WW","year":"1995"},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/0149-2918(95)80102-2","article-title":"ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia","volume":"17","author":"Fabre LF","year":"1995","journal-title":"Clin Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0149-2918","issn-type":"print"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/00004714-199604000-00008","article-title":"ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia","volume":"16","author":"Borison RL","year":"1996","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"3","key":"ref54","doi-asserted-by":"crossref","DOI":"10.1016\/0924-977X(94)90213-5","article-title":"A multicentre, placebo-controlled double-blind evaluation of SeroquelTM in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia","volume":"4","author":"Arvanitis L","year":"1994","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"3","key":"ref55","first-page":"346","article-title":"SeroquelTM treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia: A multicentre, placebo-controlled, double-blind comparison of low and high dosage regimens","volume":"5","author":"Link CGG","year":"1995","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref56","first-page":"297","article-title":"Efficacia e tollerabilita dell' antipsychotico atipico quetiapina: uno studio in doppio cieco","volume":"40","author":"Barzega G","year":"1999","journal-title":"Minerva Psichiatrica","ISSN":"http:\/\/id.crossref.org\/issn\/0374-9320","issn-type":"print"},{"key":"ref57","first-page":"221","article-title":"Quetiapine in schizophrenic patients: a high- and low-dose double-blind comparison","volume":"14","author":"Barzega G","year":"2000","journal-title":"European Journal of Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0213-6163","issn-type":"print"},{"key":"ref58","author":"Fleischhacker WW","year":"1995"},{"key":"ref59","article-title":"'Seroquel' (ICI 204636): an atypical antipsychotic - results from Phase III","volume":"6","author":"King DJ","year":"1996","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref60","author":"King DJ","year":"1996"},{"issue":"2","key":"ref61","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s002130050603","article-title":"A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia","volume":"137","author":"King DJ","year":"1998","journal-title":"Psychopharmacology (Berl)","ISSN":"http:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"key":"ref62","article-title":"Results of a multicenter study comparing the dosage and the dosage regimen of ICI 204,636 ('Seroquel')","volume":"67","author":"Reuther E","year":"1996","journal-title":"Nervenarzt","ISSN":"http:\/\/id.crossref.org\/issn\/0028-2804","issn-type":"print"},{"issue":"8","key":"ref63","doi-asserted-by":"crossref","DOI":"10.1016\/S0006-3223(00)00402-9","article-title":"Long-term treatment of quetiapine improves cognitive function in schizophrenia","volume":"47","author":"Purdon SE","year":"2000","journal-title":"Biological Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0006-3223","issn-type":"print"},{"issue":"2","key":"ref64","first-page":"137","article-title":"Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol","volume":"26","author":"Purdon SE","year":"2001","journal-title":"J Psychiatry Neurosci","ISSN":"http:\/\/id.crossref.org\/issn\/1180-4882","issn-type":"print"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1017\/S0033291799001476","article-title":"A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia","volume":"30","author":"Copolov DL","year":"2000","journal-title":"Psychol Med","ISSN":"http:\/\/id.crossref.org\/issn\/0033-2917","issn-type":"print"},{"key":"ref66","article-title":"ICI 204,636 (Seroquel): a putative new antipsychotic: results from Phase III trials","volume":"18","author":"Fleishhacker W","year":"1996","journal-title":"Schizophrenia Research","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"key":"ref67","article-title":"Switching from a conventional antipsychotic (haloperidol) to an atypical antipsychotic ('Seroquel'-ICI 204,636)","volume":"6","author":"Hellewell JSE","year":"1996","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref68","author":"Link C","year":"1996"},{"key":"ref69","series-title":"Metabotropic glutamate receptor-potentiating isoindolones","author":"Empfield JR"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","DOI":"10.1016\/0924-977X(94)90212-7","article-title":"A multicentre, double-blind, controlled comparison of SeroquelTM and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia","volume":"4","author":"Link C","year":"1994","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"4","key":"ref71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1600-0447.1997.tb10162.x","article-title":"A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia","volume":"96","author":"Peuskens J","year":"1997","journal-title":"Acta Psychiatr Scand","ISSN":"http:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"key":"ref72","author":"Buckley PF","year":"2001"},{"key":"ref73","author":"Emsley RA","year":"1999"},{"key":"ref74","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(01)80319-9","article-title":"Treatment of depressive symptoms in partially refractory schizophrenia: efficacy of quetiapine versus haloperidol","volume":"11","author":"Emsley RA","year":"2001","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref75","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(99)80283-1","article-title":"Efficacy and tolerability of 'Seroquel' compared with haloperidol in schizophrenic patients partially responsive to conventional antipsychotic treatment","volume":"9","author":"Emsley RA","year":"1999","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"3","key":"ref76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200015030-00001","article-title":"A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment: PRIZE Study Group","volume":"15","author":"Emsley RA","year":"2000","journal-title":"Int Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0268-1315","issn-type":"print"},{"issue":"1","key":"ref77","article-title":"Efficacy of seroquel in treating all of the positive and negative symptoms of schizophrenia","volume":"41","author":"Emsley RA","year":"2000","journal-title":"Schizofrenia Research"},{"key":"ref78","author":"Goldstein JM","year":"2000"},{"key":"ref79","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(01)80314-X","article-title":"Patterns of response in patients with schizophrenia partially responsive to fluphenazine and switched to quetiapine or haloperidol","volume":"11","author":"Nasrallah HA","year":"2001","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/S0924-977X(01)80315-1","article-title":"Switching from fluphenazine to quetiapine ameliorates extrapyramidal symptoms and neuroendocrine side effects in patients with schizophrenia","volume":"11","author":"Weiden PJ","year":"2001","journal-title":"European Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"key":"ref81","first-page":"1807","article-title":"Clinical evaluation of quetiapine fumarate for the treatment of schizophrenia: a double-blind controlled study using mosapramine hydrochloride as a control","volume":"16","author":"Kudo Y","year":"2000","journal-title":"Rinsyo Iyaku"},{"key":"ref82","author":"Kudo Y","year":"1999"},{"issue":"11","key":"ref83","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0149-2918(00)89080-3","article-title":"A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study","volume":"23","author":"Mullen J","year":"2001","journal-title":"Clin Ther."},{"key":"ref84","author":"Tandon R","year":"2001"},{"issue":"4","key":"ref85","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia","volume":"28","author":"Conley RR","year":"2005","journal-title":"Clin Neuropharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0362-5664","issn-type":"print"},{"issue":"1","key":"ref86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02849987","article-title":"Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study","volume":"24","author":"Gen\u00e7 Y","year":"2007","journal-title":"Adv Ther","ISSN":"http:\/\/id.crossref.org\/issn\/0741-238X","issn-type":"print"},{"issue":"1","key":"ref87","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00004714-199602000-00007","article-title":"Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients","volume":"16","author":"Blin O","year":"1996","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"1","key":"ref88","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients","volume":"13","author":"Chouinard G","year":"1993","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"4","key":"ref89","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1600-0447.1992.tb01473.x","article-title":"Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparitive study","volume":"85","author":"Claus A","year":"1992","journal-title":"Acta Psychiatr Scand","ISSN":"http:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"issue":"6","key":"ref90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1600-0447.1993.tb03480.x","article-title":"Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations","volume":"88","author":"Hoyberg OJ","year":"1993","journal-title":"Acta Psychiatr Scand","ISSN":"http:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"issue":"4","key":"ref91","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1600-0447.1995.tb09781.x","article-title":"Risperidone versus zuclopenthixol in the treatment of acute schizophrenic episodes: a double-blind parallel-group trial","volume":"91","author":"Huttunen MO","year":"1995","journal-title":"Acta Psychiatr Scand","ISSN":"http:\/\/id.crossref.org\/issn\/0001-690X","issn-type":"print"},{"issue":"6","key":"ref92","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder SR","year":"1994","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"2","key":"ref93","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3349\/ymj.1993.34.2.179","article-title":"Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial","volume":"34","author":"Min SK","year":"1993","journal-title":"Yonsei Med J","ISSN":"http:\/\/id.crossref.org\/issn\/0513-5796","issn-type":"print"},{"issue":"6","key":"ref94","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1192\/bjp.166.6.712","article-title":"Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group","volume":"166","author":"Peuskens J","year":"1995","journal-title":"Br J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0007-1250","issn-type":"print"},{"key":"ref95","author":"Potkin SG","year":"1997"},{"key":"ref96","author":"Bouchard RH","year":"1998"},{"key":"ref97","author":"Mahmoud RA","year":"1998"},{"key":"ref98","author":"Namjoshi M","year":"2002"},{"key":"ref99","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-977X(02)80471-0","article-title":"Hospitalization rates associated with olanzapine, risperidone, and haloperidol treatment in patients with schizophrenia: Results from a U.S. randomized controlled trial","author":"Namjoshi M","year":"2002","journal-title":"Eur Neuropsychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0924-977X","issn-type":"print"},{"issue":"5","key":"ref100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1176\/appi.ajp.158.5.765","article-title":"A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder","volume":"158","author":"Conley RR","year":"2001","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"6","key":"ref101","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/00019442-200311000-00008","article-title":"International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia","volume":"11","author":"Jeste DV","year":"2003","journal-title":"Am J Geriatr Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/1064-7481","issn-type":"print"},{"issue":"5","key":"ref102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/00004714-199710000-00010","article-title":"Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders","volume":"17","author":"Tran PV","year":"1997","journal-title":"J Clin Psychopharmacol","ISSN":"http:\/\/id.crossref.org\/issn\/0271-0749","issn-type":"print"},{"issue":"12","key":"ref103","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman JA","year":"2005","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"1","key":"ref104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2005.07.038","article-title":"One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia","volume":"81","author":"Keefe RS","year":"2006","journal-title":"Schizophr Res","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"3","key":"ref105","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archpsyc.57.3.249","article-title":"Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol: The Canadian Collaborative Group for research in schizophrenia","volume":"57","author":"Purdon SE","year":"2000","journal-title":"Arch Gen Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0003-990X","issn-type":"print"},{"issue":"1","key":"ref106","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/sj.npp.1300023","article-title":"Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia","volume":"28","author":"Casey DE","year":"2003","journal-title":"Neuropsychopharmacology","ISSN":"http:\/\/id.crossref.org\/issn\/0893-133X","issn-type":"print"},{"issue":"4","key":"ref107","first-page":"CD004161","article-title":"Depot risperidone for schizophrenia","author":"Hosalli P","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"ref108","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","article-title":"Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic","volume":"160","author":"Kane JM","year":"2003","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"6","key":"ref109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/hup.959","article-title":"Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone","volume":"23","author":"Suzuki T","year":"2008","journal-title":"Hum Psychopharmacol"},{"issue":"1-3","key":"ref110","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.12.030","article-title":"Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial","volume":"92","author":"Freudenreich O","year":"2007","journal-title":"Schizophr Res","ISSN":"http:\/\/id.crossref.org\/issn\/0920-9964","issn-type":"print"},{"issue":"4","key":"ref111","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/schbul\/sbj067","article-title":"Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia","volume":"32","author":"Lewis SW","year":"2006","journal-title":"Schizophr Bull","ISSN":"http:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"},{"issue":"5","key":"ref112","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer WG","year":"2006","journal-title":"N Engl J Med","ISSN":"http:\/\/id.crossref.org\/issn\/0028-4793","issn-type":"print"},{"issue":"2","key":"ref113","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht S","year":"2009","journal-title":"Am J Psychiatry","ISSN":"http:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"3","key":"ref114","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1590\/S1516-44462005000300005","article-title":"Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia","volume":"27","author":"Rosa MA","year":"2005","journal-title":"Rev Bras Psiquiatr"},{"issue":"9618","key":"ref115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial","volume":"371","author":"Kahn RS","year":"2008","journal-title":"Lancet","ISSN":"http:\/\/id.crossref.org\/issn\/0099-5355","issn-type":"print"},{"issue":"2","key":"ref116","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll CU","year":"2009","journal-title":"Schizophr Bull","ISSN":"http:\/\/id.crossref.org\/issn\/0586-7614","issn-type":"print"}],"container-title":["Sao Paulo Medical Journal"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/spmj\/v128n3\/v128n3a07.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,21]],"date-time":"2017-05-21T05:41:45Z","timestamp":1495345305000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1516-31802010000300007&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":116,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["S1516-31802010000300007"],"URL":"https:\/\/doi.org\/10.1590\/s1516-31802010000300007","relation":{},"ISSN":["1516-3180"],"issn-type":[{"value":"1516-3180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}